多瑞医药：在研新药益肺济生颗粒已完成Ⅱ期临床病例入组

Group 1 - The core viewpoint of the article is that the company primarily focuses on collaborative research and development for its innovative drugs, with a specific mention of the Yilung Jisheng Granules currently in clinical trials [1] - As of the end of December 2024, the Yilung Jisheng Granules have completed the enrollment of Phase II clinical trial cases, indicating positive progress in the drug's development [1] - The market outlook for Yilung Jisheng Granules is described as broad, suggesting potential for significant market opportunities once the drug is launched [1]